<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209801">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356395</url>
  </required_header>
  <id_info>
    <org_study_id>2003-008</org_study_id>
    <nct_id>NCT00356395</nct_id>
  </id_info>
  <brief_title>Safety and Effects of Ramipril Combined With Candesartan</brief_title>
  <official_title>Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <brief_summary>
    <textblock>
      we hypothesized that combination therapy has additive beneficial effects to improve
      endothelial dysfunction and adipocytokine profiles in patients with hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16
      mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled
      cross-over trial with three treatment arms and two washout periods (each 2 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of endothelium-dependent dilation among the 3 treatment schemes</measure>
  </primary_outcome>
  <enrollment>40</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril, candesartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with mild to moderate hypertension

        Exclusion Criteria:

          -  We will exclude patients with severe hypertension, unstable angina, acute myocardial
             infarction, or renal insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang K Koh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, Gil Heart Center, Gachon Medical School</affiliation>
  </overall_official>
  <verification_date>March 2006</verification_date>
  <lastchanged_date>July 25, 2006</lastchanged_date>
  <firstreceived_date>July 25, 2006</firstreceived_date>
  <keyword>endothelial function, insulin resistance, adipocytokines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
